Actively Recruiting
Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy
Led by Peking University Cancer Hospital & Institute · Updated on 2023-08-14
10
Participants Needed
1
Research Sites
153 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the retention in tumour and distribution behavior of \[Lu-177\]-Catalase after intratumoral injection,and preliminary evaluation the efficacy and safety of \[Lu-177\]-Catalase.
CONDITIONS
Official Title
Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 18 to 70 years with ECOG score 0 or 1
- Diagnosed advanced malignant tumors such as liver cancer, ovarian cancer, or prostate cancer confirmed by pathology or cytology
- Patients with advanced solid tumors who have failed or cannot tolerate standard treatment
- Expected survival of more than 3 months
- At least one measurable tumor lesion suitable for intratumoral injection with a longest diameter of 10 mm or more (or lymph nodes with a short diameter of 15 mm or more)
- Blood tests showing WBC 4.0�d7 10^9/L or neutrophils 1.5�d7 10^9/L, platelets 100�d7 10^9/L, hemoglobin 90 g/L; PT or APTT 1.5 times upper limit of normal
- Liver and kidney function within specified limits including T-Bil 1.5 times upper limit, ALT/AST 2.5 times upper limit (or 5 times if liver metastasis), ALP 2.5 times upper limit (or 4.5 if bone or liver metastasis), BUN and SCr 1.5 times upper limit
- Women must use effective contraception during and for 6 months after the study; men must agree to use contraception during and for 6 months after
- Ability to understand and voluntarily sign informed consent with good compliance
You will not qualify if you...
- Severe abnormal liver and kidney function
- Pregnant or breastfeeding women
- Unable to lie flat for at least half an hour
- Refusal to participate in the clinical trial
- Suffering from claustrophobia or other mental illness
- Any other conditions the investigator deems unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhi Yang
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here